阿维菌素
阿维链霉菌
天然产物
生化工程
多元化(营销策略)
生物
生物技术
抗寄生虫药
计算生物学
合成生物学
抗寄生虫的
链霉菌
业务
药理学
生物化学
遗传学
细菌
医学
工程类
病理
解剖
营销
作者
Ying Zhuo,Tao Zhang,Qi Wang,Pablo Cruz‐Morales,Buchang Zhang,Mei Liu,Francisco Barona‐Gómez,Lixin Zhang
标识
DOI:10.1002/biot.201200383
摘要
Natural products are still key sources of current clinical drugs and innovative therapeutic agents. Since wild-type microorganisms only produce natural products in very small quantities, yields of production strains need to be improved by breaking down the precise genetic and biochemical circuitry. Herein, we use avermectins as an example of production improvement and chemical structure diversification by synthetic biology. Avermectins are macrocyclic lactones produced by Streptomyces avermitilis and are well known and widely used for antiparasitic therapy. Given the importance of this molecule and its derivatives, many efforts and strategies were employed to improve avermectin production and generate new active analogues. This review describes the current status of synthetic strategies successfully applied for developing natural-product-producing strains and discusses future prospects for the application of enhanced avermectin production.
科研通智能强力驱动
Strongly Powered by AbleSci AI